Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA

Inclusion Criteria: Enroll a patient in this study if the patient meets the following inclusion criteria: * Provides written Informed Consent and is willing to comply with protocol requirements; * Is at least 18 years of age; * Is scheduled to undergo peripheral DSA for the diagnosis and/or treatment (PTA) of PAOD. Exclusion Criteria: Exclude a patient from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed: * Is a pregnant or lactating female. Exclude the possibility of pregnancy: * by testing on site at the institution (serum or urine βHCG) within 24 hours prior to the start of investigational product administration, * by surgical history (e.g., tubal ligation or hysterectomy), * post menopausal with a minimum 1 year without menses; * Has any known allergy to one or more of the ingredients of the investigational products; * Has a history of severe congestive heart failure \[class IV in accordance with the classification of the New York Heart Association (NYHA)\] * Was previously entered into this study or received an investigational compound within 30 days before admission into this study; * Has a history of hypersensitivity to iodinated contrast agents; * Has renal impairment (eGFR \<60 mL/min/1.73 m2, calculated using the Modification of Diet in Renal Disease \[MDRD\] study equation , ); * Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or postdose follow-up examinations.